



Dear {{accTitle}} {{accLname}},

Thank you for your interest in joining us at mHSPC Treatment Paradigm held on 24th June 2024.

You can watch the full recording of the webinar
[Click Here](#)

The key highlights from the webinar - **Xtandi + ADT improved the overall survival of mHSPC patients by 34% vs Placebo + ADT**

Looking forward to have further discussion on elaborated points.

Sincerely,
{{userName}}
{{User.Title}}

In case of any suspected adverse events or any safety information associated with our products, please report immediately to: Email:

Pharmacovigilance.ae@astellas.com Or contact the following number: Tel:

+966 11 2218300 / +966 11 2218500

Mob: +966 53 7070 557 In case of any medical inquiry, please contact:

Medinfo.MiddleEas-sm@astellas.com

Astellas and the Flying Star logo are registered trademarks of Astellas Pharma Inc.

The National Pharmacovigilance Center (NPC) SFDA Call Center: 19999 Email:

npc.drug@sfd.gov.sa Website: <https://ade.sfda.gov.sa> Fax: +966 11 2057662



If you no longer wish to receive professional marketing e-mail communications from Astellas, unsubscribe here.
For more information about your privacy rights and how we protect your personal information, please view our privacy notice.



MAT-SA-XTD-2024-00008/Date of preparation: July 2024